Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377173 | 0.83 | ALDH1A1 (0.64) | ALDH1A1HSD17B10POLBGAARAB9A | |
| SCHEMBL5038420 | 0.83 | ALDH1A1 (0.61) | ALDH1A1HSD17B10POLBGAARAB9A | |
| SCHEMBL11927276 | 0.79 | GAA (0.73) | ALDH1A1POLBGAARAB9AMAPT | |
| SCHEMBL999575 | 0.78 | ALDH1A1 (1.00) | ALDH1A1HSD17B10POLBGAARAB9A | |
| SCHEMBL16160314 | 0.78 | GAA (0.47) | ALDH1A1POLBGAARAB9AMAPT | |
| SCHEMBL7971675 | 0.77 | ALDH1A1 (0.57) | ALDH1A1HSD17B10POLBGAARAB9A | |
| SCHEMBL11941535 | 0.76 | GAA (0.46) | ALDH1A1HSD17B10POLBGAARAB9A | |
| SCHEMBL4678070 | 0.76 | ALDH1A1 (0.74) | ALDH1A1HSD17B10POLBGAARAB9A | |
| SCHEMBL11937209 | 0.75 | POLB (0.50) | ALDH1A1POLBGAARAB9AMAPT | |
| SCHEMBL9217566 | 0.75 | ALDH1A1 (0.50) | ALDH1A1HSD17B10POLBGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745447-B2 | Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745447-B2 | Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745447-B2 | Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1951727-A1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007050723-A1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050723-A1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093508-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093508-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093508-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093508-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | MCHR1, MCHR2, MC1R | ALDH1A1 622/4885HSD17B10 696/4885POLB 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.